The effect of micronization method on characterization and deposition profiles of different dry powder formulations of cefotaxime sodium
Najafabadi, A.R.; Asgharian, R.; Tajerzadeh, H.; Gilani, K.; Vatanara, A.; Darabi, M.
Journal of Drug Delivery Science and Technology 16(5): 363-368
2006
Accession: 073520209
PDF emailed within 1 workday: $29.90
Related References
Nassar, M.W.I.; El Sattar, O.I. Abd; Barakat, S.E.M. 1996: Colorimetric and titrimetric determination of cefotaxime sodium in bulk powder and pharmaceutical formulations Egyptian Journal of Pharmaceutical Sciences 37(1-6): 175-187Rouholamini-Najafabadi, A.; Asgharian, R.; Tajerzadeh, H.; Gilani, K.; Vatanara, A.; Darabi, M. 2006: The effects of fine lactose as a third component on aerosolization of cefotaxime sodium from dry powder formulations Daru 14(3): 155-163
Lalitha, N.; Pai, P.S. 2009: Development and validation of RP-HPLC method for estimation of Cefotaxime sodium in marketed formulations Journal of Basic and Clinical Pharmacy 1(1): 26-28
Wang, Y-Bo.; Watts, A.B.; Peters, J.I.; Liu, S.; Batra, A.; Williams, R.O. 2014: In vitro and in vivo performance of dry powder inhalation formulations: comparison of particles prepared by thin film freezing and micronization Aaps Pharmscitech 15(4): 981-993
Gilani, K.; Najafabadi, A.-Rouholamini; Darabi, M.; Barghi, M.; Rafiee-Tehrani, M. 2004: Influence of formulation variables and inhalation device on the deposition profiles of cromolyn sodium dry powder aerosols Daru 12(3): 123-130
Richardson, C.H.; de Matas, M.; Hosker, H.; Mukherjee, R.; Wong, I.; Chrystyn, H. 2007: Determination of the relative bioavailability of salbutamol to the lungs following inhalation from dry powder inhaler formulations containing drug substance manufactured by supercritical fluids and micronization Pharmaceutical Research 24(11): 2008-2017
Fu, Y.; Li, J.; Feng, F.; Yin, L. 2022: Method Improving for Isolation and Characterization of Allergy-Inducing Polymer Impurities in Cefotaxime Sodium Medicines Available from Pharmaceutical Industry Frontiers in Chemistry 10: 820730
Chen, D.; Wang, H.; Zhang, Z.; Ci, L.; Zhang, X. 2011: Chemiluminescence determination of cefotaxime sodium with flow-injection analysis of cerium (IV)-rhodamine 6G system and its application to the binding study of cefotaxime sodium to protein with on-line microdialysis sampling Spectrochimica Acta. Part A Molecular and Biomolecular Spectroscopy 78(1): 553-557
Hertel, M.; Schwarz, E.; Kobler, M.; Hauptstein, S.; Steckel, H.; Scherließ, R. 2018: Powder flow analysis: a simple method to indicate the ideal amount of lactose fines in dry powder inhaler formulations International Journal of Pharmaceutics 535(1-2): 59-67
Fried, F. 1997: Application poudre pour des profilés de fenêtres et de portes en aluminium - Powder paint deposition for aluminium profiles and doors Surfaces (Paris) (268): 19-21
Taki, M.; Marriott, C.; Zeng, X.-M.; Martin, G.P. 2010: Aerodynamic deposition of combination dry powder inhaler formulations in vitro: a comparison of three impactors International Journal of Pharmaceutics 388(1-2): 40-51
Larhrib, H.; Martin, G.P.; Marriott, C.; Prime, D. 2000: Dry powder inhaler formulations The influence of engineered lactose crystals upon the deposition of salbutamol sulphate Journal of Pharmacy and Pharmacology 52(Suppl): 14
Broadhead, J.; Rouan, S.K.E.mond; Rhodes, C.T. 1993: The in vitro deposition of spray dried beta-galactosidase formulations from dry powder inhaler devices Pharmaceutical Research (New York) 10(10 Suppl): S89
Martin, G.P.; Marriott, C.; Zeng, X-Ming. 2007: Influence of realistic inspiratory flow profiles on fine particle fractions of dry powder aerosol formulations Pharmaceutical Research 24(2): 361-369
Srichana, T.; Martin, G.P.; Marriott, C. 1997: The effect of an oral cast on the lower stage deposition of dry powder inhaler formulations in a twin impinger Pharmaceutical Research (New York) 14(11 Suppl): S141-S142